Catalent (NYSE:CTLT) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of Catalent (NYSE:CTLT) from a hold rating to a sell rating in a research note issued to investors on Friday.

A number of other equities research analysts have also recently weighed in on CTLT. Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat, Catalent has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

Shares of CTLT opened at $60.98 on Friday. The company has a market cap of $11.07 billion, a PE ratio of -26.98, a price-to-earnings-growth ratio of 2.34 and a beta of 1.16. The firm has a 50-day moving average of $59.79 and a 200-day moving average of $58.26. Catalent has a one year low of $36.74 and a one year high of $61.50. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.10) EPS. As a group, equities analysts forecast that Catalent will post 0.84 earnings per share for the current year.

Insider Transactions at Catalent

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Neo Ivy Capital Management bought a new position in Catalent in the 3rd quarter valued at about $1,078,000. Nomura Asset Management Co. Ltd. raised its position in Catalent by 1.4% during the third quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock valued at $3,211,000 after purchasing an additional 750 shares in the last quarter. National Bank of Canada FI boosted its holdings in shares of Catalent by 300.0% in the 3rd quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after purchasing an additional 1,095,578 shares in the last quarter. State Street Corp raised its holdings in shares of Catalent by 1.5% during the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company’s stock worth $451,315,000 after buying an additional 113,095 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its stake in Catalent by 30.6% in the third quarter. Quantinno Capital Management LP now owns 16,290 shares of the company’s stock valued at $987,000 after buying an additional 3,817 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.